Top 50 Medical VC Funds & Investors (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
SOSV
VC Fund
|
87 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Bpifrance
VC Fund
|
60 | France, United States, Switzerland | Seed, Series A | Software, Information Technology, Health Care | $726k–$34M |
|
Qiming Venture Partners
VC Fund
|
59 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5M–$134M |
|
Innova Memphis
VC Fund
|
58 | United States, Argentina, United Kingdom | Seed, Pre-Seed | Health Care, Medical, Medical Device | $25k–$1.7M |
|
OrbiMed
VC Fund
|
57 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $10M–$151M |
|
ARCH Venture Partners
VC Fund
|
56 | United States, China, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $8.4M–$230M |
|
Alumni Ventures
VC Fund
|
54 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $1.5M–$79M |
|
Right Side Capital Management
VC Fund
|
50 | United States, Canada, United Kingdom | Seed, Pre-Seed, Convertible Note | Software, SaaS, Health Care | $20k–$2M |
|
Gaingels
VC Fund
|
46 | United States, Canada, Mexico | Seed, Series A, Series B | Software, Health Care, Artificial Intelligence | $1.1M–$100M |
|
New Enterprise Associates
VC Fund
|
46 | United States, India, United Kingdom | Series A, Series B, Series C | Software, Health Care, Biotechnology | $5.4M–$103M |
|
General Catalyst
VC Fund
|
45 | United States, United Kingdom, India | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $1.8M–$130M |
|
BioVenture
VC Fund
|
43 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $3M–$73M |
|
F-Prime
VC Fund
|
40 | United States, United Kingdom, China | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $9.2M–$165M |
|
Polaris Partners
VC Fund
|
39 | United States, Ireland, Singapore | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $4.5M–$107M |
|
Google Ventures
VC Fund
|
38 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1.1M–$121M |
|
Novo Holdings
VC Fund
|
37 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9M–$135M |
|
Antler
VC Fund
|
37 | Singapore, Australia, United Kingdom | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $108k–$28M |
|
Connecticut Innovations
VC Fund
|
37 | United States, Israel, Canada | Seed, Series A | Health Care, Biotechnology, Software | $300k–$25M |
|
Atlas Venture
VC Fund
|
37 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.5M–$115M |
|
Khosla Ventures
VC Fund
|
36 | United States, India, United Kingdom | Series A, Series B, Seed | Software, Artificial Intelligence, Health Care | $2M–$100M |
|
HSG
VC Fund
|
35 | China, United States, Hong Kong | Series A, Series B, Series C | Health Care, Biotechnology, Software | $4.4M–$214M |
|
Versant Ventures
VC Fund
|
34 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.7M–$108M |
|
Alexandria Venture Investments
VC Fund
|
33 | United States, Canada, France | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2M–$150M |
|
Sofinnova Partners
VC Fund
|
33 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6.6M–$109M |
|
Enterprise Ireland
VC Fund
|
32 | Ireland, United States, United Kingdom | Seed, Series A | Software, Information Technology, Health Care | $494k–$12M |
|
Med-Fine Capital
VC Fund
|
31 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $2.8M–$60M |
|
Wavemaker 360
VC Fund
|
30 | United States, United Kingdom, Canada | Seed, Series A, Series B | Health Care, Medical, Medical Device | $750k–$30M |
|
Canaan Partners
VC Fund
|
30 | United States, United Kingdom, Israel | Series A, Series B, Series C | Software, Biotechnology, Health Care | $5M–$75M |
|
Forbion Capital Partners
VC Fund
|
30 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $16M–$176M |
|
Third Rock Ventures
VC Fund
|
30 | United States | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$190M |
|
KdT Ventures
VC Fund
|
30 | United States, India, Canada | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $2.6M–$175M |
|
TEDCO
VC Fund
|
29 | United States, Canada, Colombia | Seed, Grant, Pre-Seed | Health Care, Software, Biotechnology | $25k–$2.5M |
|
RA Capital Management
VC Fund
|
29 | United States, United Kingdom, Canada | Series B, Series C, Post-IPO Equity | Biotechnology, Health Care, Therapeutics | $26M–$240M |
|
StartUp Health
VC Fund
|
29 | United States, Canada, United Kingdom | Seed, Pre-Seed | Health Care, Wellness, Medical | $20k–$4M |
|
Lilly Asia Ventures
VC Fund
|
28 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$283M |
|
Scottish Enterprise
VC Fund
|
28 | United Kingdom, United States, Switzerland | Grant, Seed | Biotechnology, Software, Health Care | $119k–$4.3M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
28 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $1.1M–$33M |
|
Lux Capital
VC Fund
|
28 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $1.8M–$193M |
|
Andreessen Horowitz
VC Fund
|
28 | United States, United Kingdom, Brazil | Series A, Seed, Series B | Software, Information Technology, Artificial Intelligence | $1.6M–$112M |
|
Prox Ventures
VC Fund
|
28 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $1.9M–$28M |
|
Legend Capital
VC Fund
|
27 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $2.9M–$156M |
|
8VC
VC Fund
|
26 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Health Care, Artificial Intelligence | $2.5M–$175M |
|
Cowin Venture
VC Fund
|
26 | China, United States, Hong Kong | Series A, Angel, Series B | Health Care, Medical, Biotechnology | $425k–$257M |
|
Sanofi Ventures
VC Fund
|
26 | United States, United Kingdom, France | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $9M–$150M |
|
Wisconsin Investment Partners
VC Fund
|
26 | United States, Canada, United Kingdom | Seed, Series A | Health Care, Biotechnology, Medical | $400k–$7M |
|
Shanghai Biomedical Industrial Equity Investment Fund
VC Fund
|
26 | China, United States, Hong Kong | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $8M–$142M |
|
Rock Health Capital
VC Fund
|
25 | United States, Denmark | Seed, Series A, Series B | Health Care, Software, Medical | $20k–$63M |
|
Green Park & Golf Ventures
VC Fund
|
25 | United States, Israel, Sweden | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $420k–$45M |
|
BioInnovation Institute
VC Fund
|
25 | Denmark, Germany, Switzerland | Convertible Note, Pre-Seed, Debt Financing | Biotechnology, Medical, Health Care | $500k–$5.2M |
|
Sante Ventures
VC Fund
|
25 | United States, Canada, Japan | Series A, Series B, Series C | Health Care, Medical, Biotechnology | $1.9M–$80M |
| Access all 14785 VC funds in Medical startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 1268
- Round size: Seed $726k–$6.5M; Series A $2.7M–$34M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- AQEMIA — Aqemia is an in silico drug discovery start-up, whose ambition is to discover rapidly more innovative therapeutic molecules with better chances of success.
- Probabl — Open Source Commons for AI, Machine Learning, and Data Science.
- Ostrea — OSTREA is a pioneering company in the creation of high-performance materials based on bio-minerals: seashells.
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 803
- Round size: Series A $5M–$68M; Series B $9.4M–$100M; Series C $14M–$134M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $887M in 2023
Portfolio highlights
- Chuman — Chuman is a UGC Pan-Secondary Creation Community, providing creative platforms and studios for comic creators, and providing IP incubation and resource docking services. Users can quickly generate a lot of content through third-party or official materials, and can make friends, transactions and other activities within the community through thecreation, while the APP also supports the dialogue novel reading function.
- Wholee — Wholee is a member-only zero-markup store.
- Zeen Health — Zeen Health is a digital therapeutics company that provides mental health services. Zeen Health was founded in 2019 and was headquartered in Shenzhen, China.
Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Seed, Pre-Seed
- Geography: United States, Argentina, United Kingdom
Investor stats
- Total investments: 252
- Round size: Seed $50k–$1.7M; Pre-Seed $25k–$1.3M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- HerdDogg — HerdDogg is passionate about livestock. Its innovative data platform sits at the intersection of agtech, the internet of things, and global food security. Our patented DoggTags and DoggBone, together with our Animal Traceability Platform, help producers make more money from every animal they raise. The HerdDogg system enables animal tracking,welfare monitoring and traceability in an easy-to-use application. For more information, visit herddogg.com.
- Insignum AgTech — Insignum AgTech develops biotech plants that communicate with producers, alerting them to an illness in its early stages.
- Rescue Forensics — Customer service is our #1 priority. Get a premium domain for your website today. Financing available.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 611
- Round size: Series A $10M–$140M; Series B $24M–$151M; Series C $15M–$131M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- MDClone — The MDClone ADAMS Platform is a self-service, data analytics environment powering healthcare collaboration, innovation, and data-driven projects.
- Beijing Tianxing — Beijing Tianxing is a clinical solutions company for sports medicine for implants, arthroscopy devices, and sports medicine equipment.
- Aspen Neuroscience — personalized cell therapy Starts with you Learn More about our technology
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 412
- Round size: Series A $8.4M–$213M; Series B $14M–$230M; Series C $15M–$175M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Synchron — The endovascular brain computer interface.
- Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
- HI-Bio — HI-Bio leverages human genetic and immunological insights to deliver targeted, effective medicines to patients with immune-mediated diseases.
Access curated startup investment opportunities and diversified venture capital exposure designed for accredited investors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 1791
- Round size: Seed $1.5M–$10M; Series A $5.5M–$37M; Series B $11M–$79M
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- NextDroid — NextDroid - We're Doing Something Different
- Enact — Enact is a leading solar energy and solar software company serving homeowners, businesses, and installers. Get a free quote or request a demo today!
- ARRIS — Using next-gen advanced manufacturing technologies, ARRIS Composites produces smarter, lighter, stronger, and more sustainable products at scale.
Systematic Pre-Seed Startup Capital
Show more...Investment focus
- Industry: Software, SaaS, Health Care
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 1141
- Round size: Seed $20k–$2M; Pre-Seed $50k–$448k; Convertible Note $50k–$500k
- Lead/follow: 3% lead, 97% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- tbh — tbh is a developer of a mobile application designed to provide anonymous feedback to friends. The company's mobile application facilitates asking or answering questions, open text fields and invite abuse when combined with anonymity, enabling users to say things without repercussions and feel better about themselves from the positive feedbackon social networks.
- ForwardLane — ForwardLane is a fast-growing, award-winning applied AI fintech startup that dramatically enhances productivity with AI-powered insights for financial advisors and fund distributors. Our patent-pending insight platform featuring NLP built for financial services, synthesizes data to find signals for personalized client engagement. The platformdelivers insights integrated into financial advisor and fund distributors workflows in CRM, with Salesforce being a key partner. The platform acts as a powerful "virtual analyst" reviewing all the data across all clients everyday, ranking and scoring it and then surfacing signals for growth opportunities, wallet share increase, retention conversations and awareness across the book as to who to reach out to, and what to talk about. Together this fuels organic, scalable growth through frequent, proactive personalized engagement.
- Vector ML Analytics — Vector ML is a financial analytics tool used by executives and analysts at banks and lending institutions to increase return, lower risk, and manage liquidity. It combines treasury, credit risk, FP&A, and capital market features in a single application using AI and automation, allowing for a 360-degree view of the balance sheet. Visit us atwww.vectormla.com
Gaingels is a venture investment syndicate in service of the LGBT+ community and its allies, investing in companies with LGBT+ founders and C-suite leaders at all stages of growth, as well as in more established companies resolved on building more inclusive teams, with a global portfolio of 130+ companies and $70M in deployed investment capital todate. The Gaingels network also actively supports its portfolio in identifying and recruiting diverse talent to their C-suite and board leadership teams and fosters a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, Mexico
Investor stats
- Total investments: 1006
- Round size: Seed $1.1M–$8.1M; Series A $5M–$40M; Series B $16M–$100M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- BQP — BosonQ Psi Pvt. Ltd. (BQP) is a state-of-the-art SaaS-based enterprise software venture leveraging the power of Quantum computing to speed up virtual simulations of Multiphysics and Computer-Aided Engineering (CAE) nature. BosonQ Psi is at the forefront of this quantum revolution. Our vision is to become the premier multiphysics simulation softwareusing quantum computing. Our world-class software suite will include computational science fields of fluid dynamics, structural dynamics, thermal, chemical, and aeroacoustics. With such an innovative product, we will revolutionize the computational world by enabling high-fidelity simulations that are impossible to solve with current computing technology. Further, this product will aid aerospace, automotive, energy, manufacturing, biotechnology, civil engineering, and astrophysics industries in saving millions of dollars by reducing long turnaround times of simulations used in the design process and give higher accuracy to make significant design changes for giving rise to the next generation of an electric car, eVTOL, skyscraper, or even Mars Rover.The possibility to harness the power of quantum computers is endless, and we at BQP thrive on pushing the boundaries of quantum computing technologies to serve our clients. We have made it our mission to bring these possibilities into the hands of every person - from a researcher to a scientist, from a professor to a student. Our name, BosonQ Psi, pays tribute to the great Indian physicist Dr. Satyendra Nath Bose, after whose name the elementary particle in quantum mechanics, Boson, was named and further incorporates the fundamental quantity that describes the state of the quantum particle - Psi, thus symbolizing the company's fundamental goal to contribute in India's goal to be the leader in the Quantum realm and also become a global leader in Quantum paradigm shift in coming years.
- Willow Wealth — Willow Wealth is an alternative investment platform focused on generating income streams for investors. Get exclusive access to private market investments.
- Hubble Network — Connect a Bluetooth device to a global satellite network, delivering affordable, low-power tracking and monitoring for diverse industrial and commercial applications.
Foundational partners to ambitious founders at every stage of company-building.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1581
- Round size: Series A $5.4M–$60M; Series B $10M–$77M; Series C $14M–$103M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $2.8B in 2022
Portfolio highlights
- IonQ — Working to build the world's best quantum computers to solve the world's most complex problems
- Spyglass Ophthalmics — A vision towards a higher quality of life!
- Xenon Pharmaceuticals — A leading neuroscience company forging new paths for those living with neurological and psychiatric disorders.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investing in powerful, positive change that endures
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 1839
- Round size: Seed $1.8M–$20M; Series A $6.5M–$70M; Series B $12M–$130M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Ayr Energy —
- Prosimo — Application Experience across Multi-cloud
- Empathy — Coping with the loss of a loved one is not easy. Download the Empathy App for guidance on what to expect following a loss and the tools to get you through each step.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 168
- Round size: Seed $7.1M–$41M; Series A $3.8M–$47M; Series B $3M–$73M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Dami&Xiaomi — Rice and millet is China's leading platform services for children with autism spectrum, from 2014 Nian 9 Yue Jiang Ying Shuang (rice) founded the "rice and millet" micro-channel public number. It now provides integrated services such as rehabilitation services, integrated education support, parent training, online courses, andpopular science information.
- CART Medical — CART Medical Technologies, Ltd. is a high-tech company specializing in the development and application of new technologies for immune cell therapy. It has a 2,200 square meter GMP laboratory and research and development laboratory.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 433
- Round size: Series A $9.2M–$87M; Series B $15M–$112M; Series C $22M–$165M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- NodThera — NodThera is a biotechnology company treating chronic diseases by targeting inflammation at its source.
- Logixboard — The best way for freight forwarders to give customers shipment visibility.
- Orchard Therapeutics — Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. Theseprograms include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline.The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London, San Francisco and Boston.
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, Ireland, Singapore
Investor stats
- Total investments: 461
- Round size: Series A $4.5M–$83M; Series B $7M–$107M; Series C $10M–$100M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $182M in 1998
Portfolio highlights
- Living Proof — Living Proof was created for the purpose of applying advanced technology to solve the toughest beauty challenges from a completely fresh perspective. They are a team of scientists from outside beauty, led by MIT Institute Professor Dr. Bob Langer, and beauty authorities with a shared vision: to invent efficient formulas based on entirely newmolecules and breakthrough technologies for results you can see from across the room.
- ReadyForZero — ReadyForZero creates online financial software that helps people tackle any debt and protect their credit - automatically. It's not a "debt negotiation" or "debt settlement" service. The company was co-founded by Rod Ebrahimi and Ignacio Thayer as part of Y Combinator in the Summer of 2010. ReadyForZero is aventure-backed technical product team based in San Francisco.
- Seamless Receipts — Extensive selection of high-quality domain names. Knowledgeable, friendly customer support.
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 1110
- Round size: Seed $1.1M–$16M; Series A $6M–$100M; Series B $15M–$121M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- Cord Project — Cord is incredibly simple, incredibly fast voice messaging that lets you chat with one friend or shout to a whole group of friends. Start chatting for free on iPhone or Android now.
- Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
- Cambridge Epigenetix — CEGX develops products for academia and industry, democratizing step-changes in accuracy and cost.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 350
- Round size: Series A $9M–$125M; Series B $12M–$135M; Series C $30M–$118M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Verana Health — Verana Health is assembling the largest clinical databases in medicine to empower physicians and accelerate research for patients.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Singapore, Australia, United Kingdom
Investor stats
- Total investments: 1818
- Round size: Seed $186k–$4.6M; Pre-Seed $108k–$750k; Series A $4.6M–$28M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely actively investing — fresh fund, raised $72M in 2024
Portfolio highlights
- Sapyen — We take the fear out of infertility for men. Test for it at home, without stepping out to the hospital and get personalised health recommendations to improve sperm health and increase your chances of conceiving.
- Visoid — Render your 3D models with ease! Quick and easy rendering software for architects, powered by AI. Try Visoid for free!
- One Key Access — One Key Access is an interface to the world of couriers to enable 24/7 frictionless deliveries.
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A
- Geography: United States, Israel, Canada
Investor stats
- Total investments: 259
- Round size: Seed $300k–$5.3M; Series A $2.4M–$25M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $50M in 2023
Portfolio highlights
- 1touch.io — By continuously analyzing traffic and repository stores connected to your network, our network-based solution can detect all elements on the network that are storing, processing, and sharing personal data, both internally and externally. Whether structured or unstructured data, data in motion or at rest, and even data that is unknown to you,1touch.io can track it for you.
- Emme E2MS — Emme E2MS, LLC provides energy management solutions for the light commercial and residential markets. The company offers Energy and Environmental Management System, a platform that provides environmental controls and detailed energy monitoring solutions; and +Energy that displays electricity consumption in kilowatt/hours, dollars, and bycarbon footprint. It also provides SmartSensors, heating and cooling monitor systems, wireless outdoor temperature sensors, and wireless receivers. The company was incorporated in 2012 and is based in Beaverton, Oregon.
- Mobile Sense — The traditional diagnostic market is being transformed by advances in high performance wearables. This seismic shift led by consumer products which are uncovering new patients who previously went undetected, but still require a detailed diagnosis. Mobile Sense™ is building foundational technology that enables this transformation throughoff-the-chest wearables for long term management of cardiac arrhythmias. Developed over 7 years with $4.2M in grant funding and $1.3M in seed funding, Mobile Sense™ has a platform for differentiated wearables. Our embedded algorithms coupled with non-adhesive, wireless & waterproof sensors provides high fidelity continuous ECG and PPG recordings. The automatic monitoring provides 24/7, 365 days/yr continuous detection and classification of dangerous heart arrhythmias.
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 431
- Round size: Series A $3.5M–$75M; Series B $8M–$115M; Series C $6M–$95M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Grockit — Grockit is a pioneering online social learning company. Grockit has proven that people learn more, faster through combining social learning mechanics and multi-media learning content to help people teach and learn from others. Grockit.com offers Test Prep services for GMAT, IIM CAT, LSAT, GRE, ACT, SAT and AP Calculus and AP History tests.Grockit has built a social learning test prep platform for license and direct-to-consumer products. Florida Virtual Schools, KIPP Schools, Georgetown University and other schools have deployed Grockit services.
- K36 Therapeutics — K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
- Kinaset Therapeutics — Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.
Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Series B, Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1150
- Round size: Seed $2M–$25M; Series A $5.5M–$45M; Series B $10M–$100M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $557M in 2022
Portfolio highlights
- eASIC — eASIC, a fabless semiconductor company, manufactures eASIC platforms that reduce the cost of ownership and time to production of customized silicon devices. It develops Nextreme family of devices that reduce development cost and turn-around times compared to standard cell ASICs, while reducing power consumption and unit cost for designs,Nextreme-3, a fourth generation eASIC platform, and Nextreme-2, a third generation eASIC platform. eASIC also provides easicopy ASIC that provides OEMs with a path from Nextreme-3, Nextreme-2, or Nextreme devices to a cell-based easicopy ASIC, which thereby helps OEMs reduce device cost and power consumption further, or increase performance, and eZ-IP alliance program to bring a wealth of verified eASIC-ready IP cores to help customers get to market faster. Its products are used in various applications that span from wireless infrastructure to consumer handheld devices. eASIC serves customers worldwide. Zvi Or-Bach founded eASIC in 1999, with its headquarters in Santa Clara in California with additional offices worldwide.
- Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
- CHARM Therapeutics — CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!We help founders build enduring companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 751
- Round size: Series A $4.4M–$100M; Series B $12M–$200M; Series C $26M–$214M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- MarqVision — Effortlessly discover and remove counterfeits to protect your sales and reputation.
- Midas — Midas is the first neobroker of Turkey, providing zero commission Turkish and American stocks.
- Yunzhou Zhiwei — Yunzhou Zhiwei is a high-tech startup focused on serving large-scale equipment maintenance industries such as aviation, aerospace, shipbuilding, and rail transit. It leverages smart maintenance concepts and advanced digital technologies to make complex equipment maintenance more efficient and lean. The company drives industrial transformationtoward intelligent maintenance, helping enterprises enhance growth, efficiency, and operational excellence.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 287
- Round size: Series A $4.7M–$84M; Series B $10M–$105M; Series C $12M–$108M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Graphite Bio — Graphite Bio is a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases
- Lycia Therapeutics — Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.
- Nested Therapeutics — Nested Therapeutics is a Cambridge-based VC-backed stealth biotech company. The company's focus is on finding and creating new precision oncology small-molecule drugs targeted toward cancer genes. Nested Therapeutics was established in 2021 in Cambridge, Massachusetts.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Canada, France
Investor stats
- Total investments: 262
- Round size: Seed $2M–$31M; Series A $12M–$101M; Series B $25M–$150M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- miRecule — MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.
- Deep Genomics — Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront.
- CREATE Medicines — Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 317
- Round size: Series A $6.6M–$65M; Series B $10M–$109M; Series C $12M–$100M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
- Comet Biorefining — Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosicglucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
- Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.
Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: Ireland, United States, United Kingdom
Investor stats
- Total investments: 630
- Round size: Seed $494k–$3.3M; Series A $2.2M–$12M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $1.1M in 2021
Portfolio highlights
- E-Pire — E-Pire Limited was set up on Thu the 26th of Jun 2003 in Swords Co. Dublin.
- Sidero — Sidero, founded in Athlone in 2013, is a software services company that provides agile and cloud native software innovation to help and improve any business.
- Revive Active — Revive Active health supplement is the only brand that unlocks your abundant natural energy to maximize the lifestyle you want because it’s a supplement that does not compromise on amount or quality but is abundant with fantastic ingredients. Revive Active Health Supplement is a high quality blend of 26 ingredients delivered in one convenientsachet. The unique blend of vitamins and minerals combine to provide a multitude of health benefits including natural sustained energy without the use of sugar and caffeine. The revolutionary product also brings two key Nobel prize-winning ingredients together for the first time. The combined inclusion of Coenzyme Q10 and L-Arginine further improves Revive Active’s ability to enhance energy and vitality and support a healthy immune system in regular consumers all for as little as a cup of coffee per day.Unlike traditional fish oil supplements, Revive Krill Oil is an extremely bioavailable source of EPA and DHA. Key to the enhanced absorption is the unique structure of the omega-3s. Fish oil omega-3s are found in a triglyceride form, which repel water impairing absorption in the digestive tract. Krill oil is found in a phospholipid form which attracts water promoting fast and efficient absorption. This helps deliver the essential omega-3s to the places you need it most.
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 80
- Round size: Seed $8M–$60M; Series A $2.8M–$40M; Series B $11M–$60M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $69M in 2019
Portfolio highlights
- Med-Vision — Virtual reality (VR) medical care service provider based in Hangzhou.
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
Wavemaker Three-Sixty Health is the leading U.S. early-stage (Seed and following on at the Series A) venture capital fund focused 100% on healthcare. Launched in 2018, Wavemaker 360 invested into the most promising healthcare startups in North America, with LPs from every sector of the US healthcare system. We are SEEDING HEALTHCARE'STOMORROW. We invest in healthcare disruptors and entrepreneurs that see how the industry is transforming itself and want to make a big difference.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 83
- Round size: Seed $750k–$6M; Series A $1.9M–$16M; Series B $20M–$30M
- Lead/follow: 12% lead, 88% follow
- Last fund: Likely still investing — raised $64M in 2022
Portfolio highlights
- 01Health — 01Health is a health tech building an AI-powered clinical infrastructure platform for specialist healthcare delivery.
- Lium — Lium provides a platform that structures technical datasets and makes them accessible through natural language, enabling teams to analyze, understand.
- Hermes Health — Big IdeaHermes Health is a secure, neutral middleware platform that simplifies and standardizes access to identified patient health data. We connect Requestors (e.g., attorneys, CROs, analytics firms) with Partners (e.g., ROI vendors, EHR providers, RWD sources) who hold and manage this data.ProblemAccessing identified health data remainslargely manual and outdated—relying on phone calls, faxes, and mailed records. This process is fragmented, costly, and inefficient. Requestors face a maze of disconnected workflows, while Partners are bogged down by inconsistent standards and manual tasks.SolutionHermes Health offers a scalable API and the Unity Platform to power secure, patient-consented data workflows. We reduce integration complexity and contractual friction by enabling seamless connectivity between Requestors and our network of Partners.The Unity Platform integrates with Partners as they are—plugging into existing APIs or co-developing new ones to match their systems. Whether you're a requestor or a data custodian, Hermes Health accelerates access while preserving security and compliance.
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 671
- Round size: Series A $5M–$40M; Series B $8M–$75M; Series C $7.1M–$55M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $100M in 2024
Portfolio highlights
- Lev — Save time, get great rates, and eliminate the paperwork on your next commercial real estate loan. Lev gets you financing in as little as 30 days.
- Berkshire Grey — Berkshire Grey develops a materials handling system intended to automate omnichannel fulfillment. Its system utilizes artificial intelligence, computer vision, machine learning, and novel sensing to deploy intelligent robotic systems that automate tasks never before performed by machines in commercial settings, enabling customers to achieve higheraccuracy and throughput speeds than traditional approaches as well as handle the broadest assortment of products, packaging, and parcels with ease.
- GroundWork — GroundWork delivers Unified Monitoring for Real™ with an open software platform for shockingly easy integrations and customized visualizations of cloud, virtualization, network, application, server, and storage data.GroundWork Monitor is available in free (Core) and subscription versions with support (Enterprise).GroundWork was founded in 2004 andis headquartered in San Francisco, California with partners in Asia Pacific, Europe and South America.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 198
- Round size: Series A $19M–$176M; Series B $16M–$155M; Series C $19M–$113M
- Lead/follow: 52% lead, 48% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
- Gyroscope Therapeutics — Gyroscope is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.The company explores the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatmentdelivery. Its lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON.Andrew Lotery, David Kavanagh, and Peter Lachmann co-founded Gyroscope Therapeutics in Stevenage, Herefordshire in 2016.
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States
Investor stats
- Total investments: 161
- Round size: Series A $19M–$110M; Series B $11M–$190M; Series C $14M–$146M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Septerna — Septerna is a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors
- NinePoint Medical — NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo pathology devices. The company's first goal is to develop a device that enables remote pathology, or telepathology, which would facilitate immediate review of images during diagnostic procedures. This capability could potentiallyprovide physicians with immediately actionable information and eventually allow them to pursue therapeutic remedies at the time of diagnosis. This convergence of access, diagnosis and treatment during one procedure is expected to improve patient experiences and outcomes, improve the efficiency of care and provide important savings to the healthcare system. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners.
- Jounce Therapeutics — Concentra is a biosciences company.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!KdT Ventures is the standard for early-stage frontier science investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, India, Canada
Investor stats
- Total investments: 93
- Round size: Seed $2.6M–$13M; Series A $8.5M–$70M; Series B $25M–$175M
- Lead/follow: 9% lead, 91% follow
- Last fund: Likely still investing — raised $80M in 2022
Portfolio highlights
- Zag Bio — Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
- Skeletalis — Skeletalis is a biotechnology startup focused on developing next-generation precision medicines for musculoskeletal diseases, primarily osteoporosis.
- Tacit Therapeutics — Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California.
TEDCO is an independent organization that strives to be Maryland’s lead source for entrepreneurial business assistance and seed funding for the development of startup companies in Maryland’s innovation economy.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Seed, Grant, Pre-Seed
- Geography: United States, Canada, Colombia
Investor stats
- Total investments: 288
- Round size: Seed $100k–$2.5M; Grant $50k–$1M; Pre-Seed $25k–$900k
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Omni Biosciences — Omni Biosciences is a minority women-owned biotechnology company.
- Nodal Therapeutics — Nodal Therapeutics is a venture-backed startup developing next-generation antigen-specific tolerance technology to stop autoimmune disease.
- Allegany College of Maryland — The main campus of the Allegany College of Maryland rests in Cumberland, off of Willow Brook Road. As the biggest of the school’s three campuses, Cumberland has all of the amenities you may never have expected from a small college. Each building is equipped with the latest modern facilities, making for an up-to-date learning experience. There arealso dining areas, a student lounge, and a state of the art physical education building with a gym and swimming pool.Within the list of extensive fields of study are the social, biological and political sciences, criminal justice and criminology, many fields in the humanities, accounting and business programs, automotive and other technical studies, culinary arts, hotel and restaurant management, forest technology, health fields including dental hygiene, physical education, nursing, and pharmacy technician studies, and more. Advice is not something you’ll be lacking at Allegany. The tutoring services can help you through any academic rough patches. Transfer advising can prepare you to go to a four-year college. Career advising counselors can help you pick a major, assess your interests and aptitudes, and help find you a career.Along with federal financial aid and veteran’s benefits, Allegany also offers a catalog full of scholarships from major related aid to local endowments to eligible students.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Post-IPO Equity
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 478
- Round size: Series B $26M–$151M; Series C $44M–$183M; Post-IPO Equity $35M–$240M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Curevo — focused on a new generation of adjuvanted subunit vaccines Learn More Our Focus We're dedicated to developing non-mRNA vaccines for unmet medical needs Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines. We focus on one need at a time, allowing us to bring effective and better-tolerated vaccines to market quickly
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- Terrestrial Bio — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
Organizing and investing in a global army of entrepreneurs committed to achieving health moonshots
Show more...Investment focus
- Industry: Health Care, Wellness, Medical
- Stage:Seed, Pre-Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 195
- Round size: Seed $100k–$4M; Pre-Seed $20k–$800k
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Jiseki Health — Jiseki is built on the belief that families and communities need and deserve a safety net, and to have peace of mind when things go wrong. We provide access and delivery of key advice, help, products and services through highly scalable SMS technology, powered by a combination of professionals and AI, and sold as a portable life benefit package..Text #help to 543210, to discover Jiseki services.
- Biome Analytics — Biome is an analytic applications that help cardiovascular teams do their best work. It helps forward thinking hospitals profitably transition and thrive in the new world of healthcare. During COVID-19, Biome has focused on assessing hospital capacity.
- NEXT Life Sciences — NEXT Life Sciences is developing the revolutionary Plan A™ procedure to bring the only scientifically proven technology in the category - Vasalgel® - to market.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 217
- Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $29M–$283M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
- ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
- Tmunity Therapeutics — Tmunity Therapeutics is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), universal engineered T cell platforms, and Chimeric Antigen....
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Grant, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 359
- Round size: Seed $375k–$3.9M; Grant $119k–$4.3M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- KubeNet — We are KubeNet - a multi-award winning technology solutions provider based in Glasgow. Whether it's Managed IT, IT Support, Cloud, Connectivity, Voice or Cyber Security, we're by your side as your trusted technology partner.
- Trojan Energy — Trojan Energy support the roll-out of its on-street flat and flush electric vehicle charging points, which aims to solve the issue for vehicle owners who do not have access to off-street parking.
- RAB Microfluidics — We diagnose early signs of failure in lubricated machinery and prevent equipment failure using our patented microfluidic technology and AI technology.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 583
- Round size: Seed $1.1M–$7.3M; Series A $3.5M–$33M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- DcubeD — Accelerate your space exploration through durable and affordable Release Actuators, Solar Arrays, and Deployables from DCUBED.
- FINE Legal — fine. holt Dir Dein Geld einfach, digital und ohne Risiko.
- NAVAN Technologies — NAVAN Technologies, Inc., (NAVAN) is a pre-clinical stage biotechnology company developing and commercializing its proprietary NanoStraw platform technology, which establishes a direct, physical connection into cells to overcome a huge challenge faced by researchers globally: delivering material into hard-to-transfect-cells in an efficient yetgentle and non-perturbative manne
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 551
- Round size: Seed $1.8M–$30M; Series A $7.3M–$100M; Series B $13M–$193M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $100M in 2007
Portfolio highlights
- Adimab — Premier Human Antibody Discovery and Optimization
- Kyruus Health — Kyruus Health is a care access platform that provides solutions for providers data management, patient engagement, and activation.
- Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Brazil
Investor stats
- Total investments: 1759
- Round size: Seed $1.6M–$17M; Series A $9M–$55M; Series B $16M–$112M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Tenfold — Tenfold connects systems of engagement and customer data to enable contextual continuous conversations. Get a free demo today.
- Shapeways — Shapeways is the #1 online 3D printing service company. Working with over a million customers since 2007 - Get 3D products and parts delivered to over 100 countries.
- Matik — Remove the data bottleneck & pull numbers, tables, and charts directly into decks and PDFs
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 79
- Round size: Seed $1.9M–$5.6M; Series A $2.8M–$28M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Shengxin Medical — Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group —
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 408
- Round size: Series A $2.9M–$93M; Series B $12M–$115M; Series C $14M–$156M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Pony.ai — Pony.ai is a startup that builds full-stack autonomous driving solutions. It is a pioneer in autonomous mobility technologies and services across the US and China, spearheading public-facing Robotaxi pilots in both markets. Pony.ai is committed to creating a safe and sustainable mobility future by delivering autonomous mobility everywhere.Thecompany was founded by James Peng and Tiancheng Lou in 2016 and is headquartered in Fremont, California, United States.
- Lunit — With AI, we aim to make data-driven medicine the new standard of care. We are especially focused on conquering cancer, one of the leading causes of death worldwide.
- CMind-SEMI — CMind is committed to becoming the new global leader in smartphone communication chips by concentrating on 4G and 5G advanced wireless communication chips and complete solutions.
8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 525
- Round size: Seed $2.5M–$13M; Series A $8M–$57M; Series B $17M–$175M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Karat — Karat helps companies hire top engineering talent by improving the quality, efficiency, and equity of their technical hiring process
- Apex — Apex manufactures ESPA-class satellites, ranging from 40 to 400kg. Our first spacecraft bus platform, Aries, is built for LEO missions for earth observation, communications, and more. Configure the Aries bus to meet your specific mission profile.
- Flywheel.io — Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from topuniversities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT.Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.
Founded in 2009, Cowin Venture is an angel and early-stage investor in TMT and Healthcare. We keep nurturing growth-stage companies graduated from their angel investment portfolio. Cowin’s business network covers China and USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing and Hong Kong.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Angel, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 100
- Round size: Angel $425k–$1.4M; Series A $1.4M–$25M; Series B $2.8M–$257M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- CytoChip —
- Amador Bioscience — At Amador we provide global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies.
- StringMotion Future — StringMotion Future focuses on the core technology research and development of tendon-inspired chord-driven robots, creating advanced robotic systems designed to deliver greater flexibility, precision, and efficiency for industrial and intelligent automation applications.
Sanofi Ventures invests in top tier biotherapeutic and digital health entrepreneurs who focus on helping patients and transforming the healthcare system.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 116
- Round size: Series A $9M–$81M; Series B $30M–$150M; Series C $30M–$120M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $750M in 2001
Portfolio highlights
- BranchLab — Powering the AI era of privacy-first activation to drive real-world health outcomes.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
- Star Therapeutics — Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Wisconsin Investment Partners is an Angel Investment Group in Madison, Wisconsin founded in 2000 with 20 members. Membership has grown to 50+ members in recent years, bringing significant knowledge and experience.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 115
- Round size: Seed $400k–$3M; Series A $1.1M–$7M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- DropCap — DropCap is a tech-enabled rights agency (dropcap.com) and a global rights marketplace used by rights agents and acquisitions editors around the world to find great books (dropcapmarketplace.com). Our mission is to provide independent authors and publishers access to rights licensing opportunities and help indie books go global through foreignrights, audio, and film rights licensing.
- Cylerity — Transform healthcare receivables into real-time capital. Cylerity unlocks cash flow, clarity, and control from claims data. See how it works.
- Midwest Games — Midwest Games is a video game publisher focused on creating opportunities for the abundant talent across the Midwest and other underrepresented regions.
Shanghai Biomedical Industrial Equity focuses on areas that are in line with the development strategy of the biomedical industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 67
- Round size: Seed $8M–$50M; Series A $10M–$43M; Series B $14M–$142M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Beixcell — Beixcell develops off-the-shelf cell therapies for patients with many degenerative diseases through universal iPSCs-derived cell products.
- BioGeometry — BioGeo is an innovative digital startup that specializes in using generative AI in protein creation. BioGeo is dedicated to producing programmable proteins from scratch and utilizing them in synthetic biology and biomedicine by employing artificial intelligence-driven techniques to create links between protein sequence, structure, and function.
- Surgerii Technology — Beijing Surrey is a technology company founded by an industry elite active in China's medical equipment. Relying on the core technology of the new generation of flexible continuum robotic arm, running through the implementation paradigm of many types of clinical minimally invasive surgery, and harnessing the powerful system design andintegration capabilities, Beijing Shurui is committed to becoming the first independent independent research and development, production and sales in China.
Rock Health Capital is a full-service seed fund that invests in and supports startups working in digital health. The company invests in entrepreneurs working at the intersection of healthcare and technology. Rock Health Capital is a digital health-focused investment firm.
Show more...Investment focus
- Industry: Health Care, Software, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, Denmark
Investor stats
- Total investments: 115
- Round size: Seed $20k–$4.2M; Series A $4.7M–$34M; Series B $8M–$63M
- Lead/follow: 6% lead, 94% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- Burst — Burst | FSA & HSA Checkout, Reimbursements, and LMNs anywhere
- No Barrier —
- Rosarium Health — Rosarium Health is a platform that connects service providers (home contractors and occupational therapists) with customers to execute accessible house assessments and accessible home modifications at a client's primary home, leased property, or company.
Green Park & Golf, built on over 50 years of operational and financial experience, seeks investment opportunities that offer above-market returns for its investors. Led by Clay Heighten, M.D., and Carl Soderstrom, the Firm delivers strategic solutions, financial backing and a reliable network to its portfolio companies. The Dallas-based Firm iscurrently looking for investment opportunities in medical-related start-ups.Dr. Heighten founded MedicalEdge Healthcare Group in 1993, and Mr. Soderstrom started PhyServe Physician Services in 1998 to administer the financial and operational needs of MedicalEdge. Together, the companies managed over 550 providers in five major markets. In 2011, the companies were sold to Texas Health Resources, a $3.8 billion health care system. That’s when Green Park & Golf was born.After earning his MBA at Southern Methodist University, Mr. Garcia joined them full-time in May 2011 to actively pursue new investment opportunities and monitor other investments in their portfolio. He has prior professional experience at FedEx, Bold Ventures, and Lone Star Investment Advisors.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: United States, Israel, Sweden
Investor stats
- Total investments: 93
- Round size: Seed $420k–$3.2M; Series A $1.3M–$18M; Series B $2.1M–$45M
- Lead/follow: 13% lead, 87% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Vellum Health — Vellum Health platform provides on-demand IV enablement & treatment optimized for provider organizations, payers, clinicians, and patients.
- Affineon Health — Affineon is the AI inbox that saves provider time. We automatically handle normal and clinically insignificant lab results, and help providers get through abnormal lab results faster. Our AI automatically groups, analyzes, and trends lab results into a smart summary, including possible next steps and a complete patient note. We also route"noise" to staff, reducing the number of messages a physician needs to pay attention to by up to 30%. The result is 5+ hours saved per week per provider. Plus, Affineon tightly integrates with the EHR, so providers don’t need to change their existing workflow.
- Mobia Medical — MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases. Its therapies include paired vagus nerve stimulation system (Paired VNS System) and wireless neurostimulation system for the treatment of chronic pain, post-stroke upper limb mobility issues, and variousneurological indications that enable healthcare practitioners to treat post-stroke upper limb mobility issues.Founded in 2007, MicroTransponder is headquartered in Dallas, Texas.
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Pre-Seed, Debt Financing
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 87
- Round size: Pre-Seed $516k–$5.2M; Debt Financing $533k–$1.4M; Convertible Note $500k–$1.5M
- Lead/follow: 92% lead, 8% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Loma Therapeutics — Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.
- metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Privately Held Companies
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, Canada, Japan
Investor stats
- Total investments: 118
- Round size: Series A $1.9M–$32M; Series B $2.6M–$61M; Series C $5M–$80M
- Lead/follow: 62% lead, 38% follow
- Last fund: Likely still investing — raised $260M in 2021
Portfolio highlights
- REVELOHEALTH — REVELOHEALTH provides advisory services. Their services include healthcare provider solutions, revenue cycle solutions, price transparency solutions, payment integrity, network claim repricing, data analytics, denial management, and direct-to-employer.
- Sonire Therapeutics — Sonire Therapeutics provides High-Intensity Focused Ultrasound treatment for cancer.
- SONIRE Therapeutics — SONIRE Therapeutics is a clinical-stage medical device company. It is a U.S. subsidiary of SONIRE Therapeutics Co., Ltd..
Medical VC funding at a glance
Stats across 23k deals from 15k investors.
Access all 14785 VC funds in Medical startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical VC Funds investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 14785 VC funds investing in Medical startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!